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Summary
Background: Chronic obstructive pulmonary disease
(COPD) is a complex disorder characterized by increased
oxidative stress. Functional genetic variants of phase I and
II genes are implicated in oxidants–antioxidants imbalance
and may be involved in COPD development. In this study,
we aimed to investigate the role of cytochrome P450
(CYP), glutathione S-transferase (GST) and microsomal
epoxide hydrolase (mEH) functional variants in the patho-
genesis of COPD in a Serbian population. 
Methods: The genotypes of 122 COPD patients and 100
controls with normal lung function were determined for
CYP1A1 *1A/*2A, CYP2E1 *1A/*5B, GSTM1 null,
GSTT1 null GSTP1 Ile105Val, mEH Tyr113His and mEH
His139Arg gene variants.
Results: Results obtained showed that GSTM1 null variant
was significantly more represented in COPD patients than
in controls (61.5% vs. 47.0%; OR=1.80; p=0.042). Also,
a significant difference was observed for combinations of
GSTM1 null and GSTP1 105Val/(Val) (38.5% vs. 24.0%;
OR=1.98; p=0.029), as well as for CYP1A1 *1A/*2A,
Kratak sadr`aj
Uvod: Hroni~na opstruktivna bolest plu}a (HOBP) jeste
slo`eno oboljenje koje karakteri{e povi{en oksi dativni stres.
Funkcionalne varijante gena faze I i II ksenobioti~kog meta -
bolizma mogu uticati na ravno te`u oksidanti–antioksidanti i
mogu dovesti do razvoja HOBP. Cilj ove studije je bio ispi -
tivanje uloge funkcionalnih genskih varijanti u genima za
citohrom P450 (CYP), glutation S-transferazu (GST) i mi -
kro zomalnu epoksidnu hidrolazu (mEH) u patogenezi
HOBP u srpskoj populaciji. 
Metode: U ovoj studiji analizirane su genske varijante
CYP1A1 *1A/*2A, CYP2E1 *1A/*5B, GSTM1 null, GSTT1
null, GSTP1 Ile105Val, mEH Tyr113His i mEH His139Arg
u grupi obolelih od HOBP koja je obuhvatala 122 ispita -
nika i kontrolnoj grupi koja je obuhvatala 100 ispitanika sa
normalnom funkcijom plu}a.
Rezultati: Dobijeni rezultati su pokazali da je GSTM1 null
varijanta statisti~ki zna~ajno povi{ena u grupi obolelih od
HOBP u pore|enju sa kontrolnom grupom (61,5% i
47,0%; OR=1,80; p=0,042). Tako|e, uo~ena je zna~ajna
razlika u zastupljenosti kombinacije genotipova GSTM1
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Introduction
Chronic obstructive pulmonary disease (COPD)
is a common preventable and treatable disease, char-
acterized by persistent airflow limitation that is usual-
ly progressive and associated with an enhanced
chronic inflammation response in the airways and the
lung to noxious particles or gases, as defined by the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD, 2011). COPD manifests in two major forms:
chronic bronchitis and emphysema, that commonly
coexist in the same individual (1).
Although cigarette smoking is the main risk factor
for COPD, the role of genetic determinants is empha-
sized by the evidence that only 25% of continuous
smokers develop this disease (2). Additionally, family
and twin studies suggested genetic influence on pul-
monary function and correlation of the rate of airflow
obstruction in COPD relatives (3). Severe a1-anti -
trypsin deficiency demonstrates the influence of ge -
netic determinants in the pathogenesis of COPD (3).
How ever, only a small fraction of COPD cases could be
explained by the deficiency of a1-antitrypsin, which is
in accordance with the data for a Serbian population
(4). Furthermore, exposure to indoor and outdoor air
pollutants, infectious and noninfectious agents during
childhood, as well as socioeconomic status might
play an important role in COPD development (5).
Altogether, COPD is a complex disease influenced by
multiple genetic and environmental factors, including
their interactions.
Foreign chemical compounds inhaled into the
lung are rapidly absorbed and processed in the
metabolism of xenobiotics composed of phase I and
II enzyme systems. Phase I enzymes include the cyto -
chrome P450 system (CYP) involved in the bioactiva-
tion, while phase II enzymes, glutathione S-trans-
ferase (GST) and microsomal epoxide hydrolase
(mEH), are involved in the detoxification (6). 
The CYP1A1 enables metabolic activation of
procarcinogenic substances from tobacco smoke,
including polycyclic aromatic hydrocarbons (PAH)
and aromatic amines. T3801C (CYP1A1*2A) variant,
in the 3’ flanking region of the gene, is associated
with two-fold higher enzyme activity (7). The CYP2E1
is implicated in the activation of nitrosamines from
cigarette smoke. Two variants in the 5’ flanking
region of the CYP2E1 gene, in complete linkage dis-
equilibrium, form the alleles CYP2E1 *1A (PstI – and
RsaI +) and CYP2E1 *5B (PstI + and RsaI –).
CYP2E1 *5B allele is linked with reduced enzyme
activity and inducibility (8–10). The GSTs supergene
family encodes isoenzymes that catalyse the conjuga-
tion of reduced glutathione with electrophilic com-
pounds and metabolize toxic substrates in tobacco
smoke, such as PAHs, methyl-halogens and diol-
epoxides (11). In the GSTM1 and GSTT1 genes, a
homozygous deletion variant (GSTM1 null and
GSTT1 null) results in complete lack of enzymes
activity. In the GSTP1 gene, transition at A+313G
nucleotide leads to the Ile105Val amino acid substitu-
tion and altered catalytic activity (12). The mEH cat-
alyzes the hydrolysis of arenes and aliphatic epoxides
to dihydrodiols. Two functional variants in the mEH
gene are Tyr113His, de noted as the slow allele and
connected with 39% decreased enzyme activity, and
His139Arg, denoted as the fast allele and connected
with 25% increased enzyme activity (13).
Oxidative stress is recognized as a major predis-
posing factor in the COPD pathogenesis (14). Since
genetic variants of phase I and II genes may be in -
volved in the oxidants–antioxidants imbalance, their
role in COPD pathogenesis was extensively studied.
Never theless, data concerning the possible contribu-
tion of phase I and II gene variants in the de ve lop ment
of COPD in the Serbian population is still lacking.
In this study, we investigated the role of the
functional gene variants of CYP1A1, CYP2E1,
GSTM1, GSTT1, GSTP1 and mEH genes in COPD in
a Serbian population. The single and combined geno-
types were analyzed in a group of COPD patients and
in controls with normal lung function.
Material and Methods
Subjects and study design
The patient group consisted of 122 patients
with COPD (66 with chronic bronchitis and 56 with
GSTM1 null and mEH 113His/(His) genotypes (7.4% vs.
1.0%; OR=7.88; p=0.025).
Conclusions: These are the first data concerning the analy-
sis of the variants of phase I and II genes in the pathogen-
esis of COPD in a Serbian population. Results obtained in
this study open up the possibility for thorough analyses of
the role of genetic factors in COPD on larger cohorts. Also,
they implicate the importance of previously described
genetic associations with COPD in our population, as well
as reveal a new one, not reported so far.
Keywords: COPD, candidate gene association study,
genetic variation, oxidative stress
null i GSTP1 105Val/(Val) (38,5% i 24,0%; OR=1,98;
p=0,029), kao i kombinacije CYP1A1 *1A/*2A, GSTM1
null i mEH 113His/(His) (7,4% i 1,0%; OR=7,88;
p=0,025).
Zaklju~ak: Ovo su prvi podaci o ulozi genskih varijanti gena
faze I i II u patogenezi HOBP u srpskoj populaciji. Rezultati
dobijeni u ovoj studiji otvaraju mogu}nost za detaljniju ana -
lizu uloge geneti~kih faktora u HOBP na ve}im grupama
ispitanika. Pored toga, podaci dobijeni u na{oj studiji po -
tvr|uju va`nost geneti~kih determinanti povezanih sa HOBP
u prethodnim studijama, ali tako|e otkrivaju nove geneti~ke
faktore, koji nisu objavljeni do sada.
Klju~ne re~i: HOBP, asocijativna studija gena kandidata,
genska varijanta, oksidativni stres
J Med Biochem 2015; 34 (2) 209
emphysema) recruited from the Clinical Center of
Serbia and Zvezdara University Medical Center from
2002 to 2010. The diagnosis was established based
on medical history, physical examination, pulmonary
function tests, blood gas analyses and chest radiogra-
phy, according to GOLD. The inclusion criteria for
COPD were as follows: forced expiratory volume in
one second (FEV1)/forced vital capacity (FVC) of
<70%, postbronchodilator FEV1 of <80% of the pre-
dicted value for age and height, and short-acting b2
agonist (SABA) reversibility of <12% and 200 mL of
prebronchodilator FEV1. The control group encom-
passed 100 unrelated subjects from the same geo-
graphic area, without clinical evidence of COPD, with
normal pulmonary function and parameters
FEV1/FVC>70%, as well as FEV1 >80%. 
The study was approved by the local Ethics
Com mittee, and informed consent was obtained from
each participant. 
Determination of genotypes
Genomic DNA was extracted from whole blood
using a GFX Genomic Blood DNA Purification Kit
(Amersham Biosciences).
Detection of CYP1A1 *1A/*2A, CYP2E1
*1A/*5B, GSTP1 Ile105Val, mEH Tyr113His and
mEH His139Arg variants was performed using poly-
merase chain reaction-restriction fragment length
polymorphism (PCR-RFLP), while the presence of
GSTM1 and GSTT1 deletions was analyzed by a mul-
tiplex PCR method, as previously described (15–19).
Alleles were separated on agarose gel electrophoresis
and visualized with ethidium-bromide staining and
UV transillumination. Genotypes were scored without
knowledge of the sample phenotypes by two inde-
pendent observers.
Statistical analysis
The age of patients, representing the age when
COPD was diagnosed, age of control subjects at the
time of medical check-up for the study, and pul-
monary function data were expressed as mean ±
standard deviation. Clinical data of the patients and
controls were compared using c2-test or Student’s t-
test, as appropriate. Deviations of genotype distribu-
tions from the Hardy–Weinberg equilibrium were
assessed by c2-test for each cohort. The association
of alleles, single and combined genotypes with the
COPD status was tested by Fisher’s exact test. Odds
Ratios (ORs) and 95% Confidence Intervals (95% CIs)
were calculated. A p-value of less than 0.05 was con-
sidered significant. Statistical analysis was performed
using SPSS (Statistical Package for the Social
Sciences).
Results
Clinical characteristics
The main characteristics and clinical parameters
of patients with COPD and control subjects are shown
in Table I. The mean age of control subjects was high-
er and males were more frequent in the patient
group. The mean FEV1 and FEV1/FVC were signifi-
cantly decreased in the patient group. 
The role of single and combined genotypes in
COPD
All the genotype distributions were in the
Hardy– Wein berg equilibrium, with the exception of
CYP2E1 *1A/*5B variant in the control group. Since
the frequency of CYP2E1 *5B allele was 2.5%, the
homozygous carrier in the control group was not
expected (c2=14.79, df=1, p<0.05). The genotype
and allele frequency distributions of analyzed variants
in COPD and the control group are given in Table II. 
The frequency of GSTM1 null genotype was sig-
nificantly increased in patients in comparison to con-
trols (61.5% vs. 47.0%; p=0.042; Table II). The allele
and genotype frequencies of CYP1A1 *1A/*2A,
CYP2E1 *1A/*5B, GSTT1 null, GSTP1 Ile105Val,
mEH Tyr113His and mEH His139Arg did not show
significant differences between the groups  (Table II). 
In order to examine the role of the cumulative
impact of genetic variants in the pathogenesis of
COPD, the distributions of combined genotypes
including: CYP1A1 *2A, GSTM1 null, GSTT1 null,
GSTP1 105Val and mEH 113His alleles were tested
among the groups. According to the analysis, two
combined genotypes with significantly different distri-
butions among the patient and control groups were
identified in this study. The frequency of subjects with
GSTM1 null and GSTP1 Val/(Val) combination was
higher in patients in comparison to controls (38.5% vs.
24.0%), and carriers of these genotypes had two-fold
in creased risk for COPD (OR=1.98; p=0.029). The
incidence of the combination with CYP1A1 *1A/*2A,
GSTM1 null and mEH 113His/(113His) alleles was
overrepresented in the patient group (7.4% vs. 1.0%;
Table I The main characteristics and clinical parameters of
patients and controls.
COPD Controls
Subjects (n) 122 100
Age (years) 44.96±16.71a 50.9±13.66
Sex, male (%) 70a 35
Smokers (%) 70 50
FEV1 (% pred) 45.3±24.74a 110.1±16.69
FEV1/FVC 62.4±21.65a 98.3±8.57
acomparison among COPD and control group, p≤0.05.
p=0.025), while carriers of these genotypes had
eight-fold higher risk of developing COPD (OR=7.88)
(Table III).
Discussion
In this study, the distribution of the CYP1A1
*1A/*2A, CYP2E1 *1A/*5B, GSTM1 null, GSTT1
null, GSTP1 Ile105Val, mEH Tyr113His and mEH
His139Arg alleles, single and combined genotypes
were compared in a group of 122 COPD patients and
100 control subjects with normal pulmonary func-
tion. The impetus to perform an association study of
candidate genes was the lack of data concerning the
role of genetic variants of the genes involved in xeno-
biotic metabolism in COPD pathogenesis for the
Serbian population, since there might be an ethnicity-
specific genetic basis associated with the disease. The
data regarding single and combined genotypes com-
parisons were presented without correction for multi-
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Table II The allelic and genotype distributions of analyzed variants in COPD and control group.
Table III The distributions of combined genotypes.
Gene Genotype, allele
COPD
n=122 (%)
Controls 
n=100 (%) OR (95% CI) p
CYP1A1 *1A/*1A 97 (79.5) 83 (83.0) 1 1
*1A/*2A 24 (19.7) 17 (17.0) 1.21 (0.61–2.40) NS
*2A/*2A 1 (0.8) 0 (0.0) NS
*2A 26 (10.7) 17 (8.5) 1.28 (0.68–2.44) NS
CYP2E1 *1A/*1A 115 (94.3) 96 (96.0) 1 1
*1A/*5B 7 (5.7) 3 (3.0) 1.95 (0.49–7.74) NS
*5B/*5B 0 (0.0) 1 (1.0) NS
*5B 7 (2.9) 5 (2.5) 1.15 (0.36–3.69) NS
GSTM1 + 47 (38.5) 53 (53.0) 1 1
null 75 (61.5) 47 (47.0) 1.80 (1.05–3.07) 0.042
GSTT1 + 95 (77.9) 76 (76.0) 1 1
null 27 (22.1) 24 (24.0) 0.90 (0.48–1.68) NS
GSTP1 Ile/Ile 48 (39.3) 45 (45.0) 1 1
Ile/Val 59 (48.4) 46 (46.0) 1.20 (0.69–2.11) NS
Val/Val 15 (12.3) 9 (9.0) 1.56 (0.62–3.92) NS
Val 89 (36.5) 64 (32.0) 1.22 (0.82–1.81) NS
mEH Tyr/Tyr 58 (47.5) 48 (48.0) 1 1
(Tyr113His) Tyr/His 48 (39.4) 40 (40.0) 0.99 (0.56–1.75) NS
His/ His 16 (13.1) 12 (12.0) 1.10 (0.48–2.56) NS
113His 80 (32.8) 64 (32.0) 1.22 (0.82–1.81) NS
mEH His/His 82 (67.2) 66 (66.0) 1 1
(His139Arg) His/Arg 38 (31.1) 29 (29.0) 1.05 (0.59–1.89) NS
Arg/Arg 2 (1.7) 5 (5.0) 0.32 (0.06–1.71) NS
139Arg 42 (17.2) 39 (19.5) 0.86 (0.53–1.39) NS
Combination of genes Genotypes COPDn=122 (%)
Controls 
n=100 (%) OR (95% CI) p
GSTM1-GSTP1
null-Val/(Val)
other
47 (38.5)
75 (61.5)
24 (24.0)
76 (76.0)
1.98 (1.10–3.57) 0.029
CYP1A1-GSTM1-mEH
*1A/*2A-null-113His/(His)
other
9 (7.4)
113 (92.6)
1 (1.0)
99 (99.0)
7.88 (0.98–63.34) 0.025
ple tests (Bonferroni correction) due to several rea-
sons. The aim of this study was to evaluate the role of
functional variants of candidate genes for COPD
pathogenesis in Serbians, since their contribution to
the disease differs in various populations, while
Bonferroni adjustment is suggested to be used in
examinations without preestablished hypotheses (20).
Additionally, application of Bonferroni adjustment
allows different interpretation of the results depend-
ing on the number of tests performed, which from a
biological standpoint might not be reasonable when
well-studied polymorphisms suspected in the disorder
are considered. Successful elimination of xenobiotics
depends on the activity of both phases of reactions of
the xenobiotic metabolism pathway, while genetic
variants analyzed in this study may influence the
kinetics of these reactions and generate highly reac-
tive intermediates, that can exert toxicity in situ (6).
Taking this into account, coincidental presence of
functional variants linked to increased activity of
phase I and decreased activity of phase II represents
a physiologically relevant reason for assessment of the
risk in carriers of combined genotypes for this com-
plex disease, while introducing Bonferroni correction
may lead to type II error and consequently negligence
of significant results (20).
We would also like to highlight that the patients
enrolled in this study were strictly selected according
to the GOLD criteria, and subjects with asthma,
malignant disease, bronchiectasis and other severe
concomitant nonpulmonary diseases were excluded
from the analysis. Apart from this, the mean age of
controls was higher in comparison to the mean age of
diagnosed COPD in the patient group, which should
not affect the results since control subjects did not
suffer pulmonary diseases in their lifetime. Also,
females were more frequent in our control group,
which may represent a confounding factor in our
study. In regard to this, we would like to emphasize
that women may be characterized by increased sus-
ceptibility, faster rate of FEV1 decline, more hospitali-
sation, more dyspnea and more deaths from COPD
than men, suggesting our control group may be more
susceptible to COPD (21). Accordingly, it is important
to stress that all our control subjects had normal lung
function and had no evidence of any lung disease
previously, a condition set up in order to ensure the
quality of chosen participants and validity of results
obtained. However, since a difference in gender dis-
tribution between the groups was observed, caution
in the interpretation of our findings is recommended. 
According to the results of our study, the distri-
bution of heterozygotes for CYP1A1 *1A/*2A variant
in patients (19.7%) and the control group (17.0%)
was similar. In studies of Japanese and Indian popula-
tions, *2A variant was associated with centriacinar
emphysema in patients with lung cancer and COPD,
while other studies conducted on Caucasians and the
Japanese failed to confirm its role in COPD and lung
cancer (22–25). 
The enzyme CYP2E1 is involved in the meta -
bolism of nitrosamines from cigarette smoke. The fre-
quency of CYP2E1 *5B allele in our controls was
2.5%, which is in concordance with the results
obtained for Caucasians (16). In total, three hetero -
zygotes and one homozygote with *5B allele were
detected, resulting in absence of the Hardy–Weinberg
equilibrium in our control group. Since the lack of
Hardy–Weinberg equilibrium might result from geno-
typing errors, inbreeding, genetic drift or population
substructure, our results were regenotyped, the sub-
jects were not related and uniformly originated from
the whole Serbian territory (26). Besides, absence of
the Hardy–Weinberg equilibrium may implicate a
connection between the genetic variant examined
and the selected group, with obligatory normal lung
function and no evidence of any lung disease previ-
ously in our controls. The *5B allele is related to
reduced enzyme activity and inducibility, and is char-
acterized by reactive oxygen species (ROS) produc-
tion even in the absence of substrate, which might
explain its connection with the normal lung function
of control subjects (8–10). Our results showed no sig-
nificant differences in the distribution of *5B variant
in patients (2.9%) and controls (2.5%), while the data
published for other populations were controversial
(24, 27, 28). 
GST enzymes have a key position in biological
detoxification processes. In Caucasians, the frequen-
cy of GSTM1 null is approximately 50%, and for
GSTT1 null about 24%, which is in concordance with
the results in our controls, 47% and 24% respective-
ly. Results of our study showed significantly higher fre-
quency of GSTM1 null in patients than in controls
(61.5% vs. 47.0%; p=0.042, respectively), while the
frequency of GSTT1 null was similar among the
groups (22.1% vs. 24.0%) (Table II). Considering the
role of GSTM1 null and GSTT1 null variants in COPD
pathogenesis, studies conducted in France, Taiwan,
Brazil, Korea, Turkey, Switzerland and Tunisia gave
controversial results that might be explained by the
different genetic disease associations in different pop-
ulations (24, 29–34). 
Among the various isoforms, GSTP1 is expressed
more abundantly in alveoli, alveolar macrophages and
respiratory bronchioles, and may play an important
role in detoxification in the lung. It  has been suggest-
ed that GSTP1 105Val has a higher catalytic efficien-
cy to the metabolism of carcinogenic aromatic epox-
ides (18). In a study on Turkish and Japanese
populations, 105Ile was connected with COPD, while
in the research on Indian, Tunisian and Russian po p -
ulations, 105Val allele represented a significant risk
factor for COPD (18, 32, 35–37). However, numerous
studies did not confirm the role of this polymorphism
in COPD pathogenesis, which is in concordance with
the results of our study (24, 28, 30). 
In the mEH gene two variants were detected,
Tyr113His and His139Arg. In this study, allelic and
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genotype distribution of these variants did not show
association with COPD pathogenesis. Although, in a
previous study, 113His allele was associated with
COPD, emphysema, decrease in FEV1 and severe dis-
ease, while 139Arg allele showed a protective role,
the conclusions were not consistent (19, 34, 37, 38).
However, the results of a recently performed com -
prehensive meta-analysis showed association of the
113His homozygous genotype with COPD in Cauca -
sians, while the 139Arg heterozygote was connected
with a decreased risk for COPD in Asians (39). 
Since COPD is a complex disease, a single gene
might have a small effect, while coexistence of sever-
al pathological variants might be more important in
the pathogenesis of this disorder. Our results showed
association of the GSTM1 null and GSTP1 Val/(Val)
combination with COPD in a Serbian population and
two-fold higher risk in its carriers (38.5% vs. 24.0%;
OR=1.98). Connection of GSTM1 null and GSTP1
Val/Val with COPD was reported in the study on a
Tunisian population that confirms the importance of
this combination in COPD development and the
validity of results obtained in our study (40). Another
combination, including CYP1A1 *1A/*2A, GSTM1
null and mEH 113His/(His) genotypes, was found
with higher frequency in patients (7.4% vs. 1%). The
carriers of this genotype combination have an eight-
fold higher risk for COPD (OR=7.88, p=0.025).
Oxidant–antioxidant balance is influenced not only
by xenobiotics from cigarette smoke, but also by envi-
ronmental and occupational toxic compounds.
Genetic variants of the genes involved in phase I and
II of xenobiotic metabolism might change the enzy-
matic activity and the kinetics of reactions of activa-
tion and detoxification of numerous toxic compounds
causing increased oxidative stress (6). The genotype
combinations revealed in this study may enable the
realization of toxic effects. The presence of CYP1A1
*2A allele is associated with two-fold increased
enzyme activity, and consequently increased concen-
tration of reactive PAH intermediaries. On the other
hand, deficiency of the GSTM1 enzyme, caused by a
null genotype, as well as slower mEH activity in the
presence of 113His allele, decrease phase II efficacy,
and might lead to increased oxidative stress. 
To our knowledge, this is the first study in which
the interaction of variants connected with increased
activity of phase I, CYP1A1 *2A, and deficiency or
decreased activity of phase II enzymes, GSTM1 null
and mEH 113His, was associated with COPD patho-
genesis. In a study on Taiwanese, a combination of
GSTM1 null, GSTP1 Ile/Ile and mEH 113His/(His)
with a 6.8 risk for COPD development was identified
(30). In another study, combination of GSTM1 null,
GSTT1 null and GSTP1 Ile/Ile with a risk of 2.83 for
COPD and a rapid decline in lung function was
revealed (41).
Bearing in mind that COPD is a heterogeneous
disease, identification of patients genetically suscepti-
ble to increased oxidative stress may help in the pre-
vention and control of disease symptoms by antioxi-
dant therapy, since it was found that antioxidant
supplements reduce the risk of chronic lung disease
development (14).
In conclusion, these are the first data concern-
ing the analysis of functional genetic variants of genes
involved in the metabolism of xenobiotics in the
COPD pathogenesis in Serbians. Although our small
sample size represents a limitation of the study, these
data may be useful for planning future investigations,
meta-analyses or more thorough research concerning
antioxidant therapy and COPD. Results of our study
revealed a significant correlation of one single geno-
type, GSTM1 null, and two combined genotypes of
GSTM1 and GSTP1, as well as CYP1A1, GSTM1 and
mEH, with the development of COPD. The genotype
combination identified for the first time in our study,
CYP1A1 *1A/*2A, GSTM1 null and mEH 113His/
(His), in association with smoking, occupational toxins
and community air pollution, might have a prominent
role in the generation of oxidative stress, inflamma-
tion and destruction of the lungs. Although our
results should be confirmed on a larger cohort, they
implicate the importance of ge netic associations with
COPD previously described in different ethnic back-
grounds, and also reveal a new one, not reported in
other populations tested so far.
Acknowledgements. This work was supported by
the Ministry of Education and Science, Republic of
Serbia, grant number 173008. 
Conflict of interest statement
The authors stated that have no conflicts of
interest regarding the publication of this article.
The views expressed herein represent those of
the authors and do not necessarily represent the views
or practices of the authors’ employers or any other
party.
212 Stankovi} et al.: Genetic variants of phase I and II genes in COPD 
J Med Biochem 2015; 34 (2) 213
References
1. Roggli V, Cagle P. Emphysema and chronic bronchitis. In:
Tomashefski J, Cagle P, Farver C, Fraire A, editors. Dail
and Hammar’s pulmonary pathology. New York: Sprin -
ger, 2008: 866–85.
2.  Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J.
Developing COPD: a 25 year follow up study of the gen -
eral population. Thorax 2006; 61: 935–9.
3.  Silverman EK. Progress in chronic obstructive pulmonary
disease genetics. Proc Am Thorac Soc 2006; 3: 405–8.
4.  Topi} A, Stankovi} M, Divac-Rankov A, Petrovi}-Stano -
jevi} N, Miti}-Miliki} M, Nagorni-Obradovi} L, et al.
Alpha-1-antitrypsin deficiency in Serbian adults with lung
diseases. Genet Test Mol Biomarkers 2012; 16: 1282–6.
5.  Stockley RA, Mannino D, Barnes PJ. Burden and patho-
genesis of chronic obstructive pulmonary disease. Proc
Am Thorac Soc 2009; 6: 524–6.
6.  Castell JV, Donato MT, Gómez-Lechón MJ. Metabolism
and bioactivation of toxicants in the lung. The in vitro cel-
lular approach. Exp Toxicol Pathol 2005; 57: 189–204.
7.  Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW,
Garte SJ, et al. Association between CYP1A1 genotype,
mRNA expression and enzymatic activity in humans.
Pharmacogenetics 1994; 4: 242–6.
8.  Marchand LL, Wilkinson GR, Wilkens LR. Genetic and
dietary predictors of CYP2E1 activity: a phenotyping
study in Hawaii Japanese using chlorzoxazone. Cancer
Epidemiol Biomarkers Prev 1999; 8: 495–500.
9.  Kato S, Tajiri T, Matsukura N, Matsuda N, Taniai N,
Mamada H, et al. Genetic polymorphisms of aldehyde
dehydrogenase 2, cytochrome p450 2E1 for liver cancer
risk in HCV antibody-positive Japanese patients and the
variations of CYP2E1 mRNA expression levels in the liver
due to its polymorphism. Scand J Gastroenterol 2003;
38: 886–93.
10.  Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang
CH, et al. Cytochrome P450 2E1 genotype and the sus-
ceptibility to antituberculosis drug-induced hepatitis.
Hepatology 2003; 37: 924–30.
11.  Bolt HM, Thier R. Relevance of the deletion polymor-
phisms of the glutathione S-transferases GSTT1 and
GSTM1 in pharmacology and toxicology. Curr Drug
Metab 2006; 7: 613–28.
12.  Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini
J. Molecular cloning, characterization, and expression in
Escherichia coli of full-length cDNAs of three human glu-
tathione S-transferase Pi gene variants. Evidence for dif-
ferential catalytic activity of the encoded proteins. J Biol
Chem 1997; 272: 10004–12.
13.  Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human
microsomal epoxide hydrolase: genetic polymorphism
and functional expression in vitro of amino acid variants.
Hum Mol Genet 1994; 3: 421–8.
14.  Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest
2013; 144: 266–73.
15.  Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic
linkage of lung cancer-associated MspI polymorphisms
with amino acid replacement in the heme binding region
of the human cytochrome P450IA1 gene. J Biochem
1991; 110: 407–11.
16.  Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF,
Sugimura H, et al. Cytochrome P450IIE1 genetic poly-
morphisms, racial variation, and lung cancer risk. Cancer
Res 1992; 52: 6712–15.
17.  Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J,
Winkler L, et al. A multiplex polymerase chain reaction
protocol for the simultaneous analysis of the glutathione
S-transferase GSTM1 and GSTT1 polymorphisms. Anal
Biochem 1996; 236: 184–6.
18.  Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi
T, et al. Glutathione S-transferase P1 (GSTP1) polymor-
phism in patients with chronic obstructive pulmonary dis-
ease. Thorax 1999; 54: 693–6.
19.  Smith CA, Harrison DJ. Association between polymor-
phism in gene for microsomal epoxide hydrolase and
susceptibility to emphysema. Lancet 1997; 350: 630–3.
20.  Perneger TV. What’s wrong with Bonferroni adjustments.
BMJ 1998; 316: 1236–8.
21.  Ohar J, Fromer L, Donohue JF. Reconsidering sex-based
stereotypes of COPD. Prim Care Respir J 2011; 20:
370–8.
22.  Cantlay AM, Lamb D, Gillooly M, Norrman J, Morrison
D, Smith CA, et al. Association between the CYP1A1
gene polymorphism and susceptibility to emphysema
and lung cancer. Clin Mol Pathol 1995; 48:
M210–M214.
23.  Budhi A, Hiyama K, Isobe T, Oshima Y, Hara H, Maeda
H, et al. Genetic susceptibility for emphysematous
changes of the lung in Japanese. Int J Mol Med 2003;
11: 321–9.
24.  Gaspar P, Moreira J, Kvitko K, Torres M, Moreira A,
Weimer T. CYP1A1, CYP2E1, GSTM1, GSTT1, GSTP1,
and TP53 polymorphisms: do they indicate susceptibility
to chronic obstructive pulmonary disease and non-small-
cell lung cancer? Genet Mol Biol 2004; 27: 133–8.
25.  Vibhuti A, Arif E, Mishra A, Deepak D, Singh B, Rahman
I, et al. CYP1A1, CYP1A2 and CYBA gene polymor-
phisms associated with oxidative stress in COPD. Clin
Chim Acta 2010; 411: 474–80.
26.  Silverman EK, Palmer LJ. Case-control association stud-
ies for the genetics of complex respiratory diseases. Am
J Respir Cell Mol Biol 2000; 22: 645–8.
27.  Arif E, Vibhuti A, Alam P, Deepak D, Singh B, Athar M,
et al. Association of CYP2E1 and NAT2 gene polymor-
phisms with chronic obstructive pulmonary disease. Clin
Chim Acta 2007; 382: 37–42.
28.  Korytina GF, Yanbaeva DG, Babenkova LI, Etkina EI,
Victorova TV. Genetic polymorphisms in the cyto -
chromes P-450 (1A1, 2E1), microsomal epoxide hydro-
lase and glutathione S-transferase M1, T1, and P1
genes, and their relationship with chronic bronchitis
and relapsing pneumonia in children. J Mol Med 2005;
83: 700–10.
29.  Elsammak YM, Attia A, Suleman M. Fibroblast growth
factor-23 and hypophosphatemia in chronic obstructive
pulmonary disease patients. J Med Biochem 2012;
31:12–8. 
30.  Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymor-
phism of epoxide hydrolase and glutathione S-transferase
in COPD. Eur Respir J 2004; 23: 818–24.
31.  Yim JJ, Park GY, Lee CT, Kim YW, Han SK, Shim YS, et
al. Genetic susceptibility to chronic obstructive pul-
monary disease in Koreans: combined analysis of poly-
morphic genotypes for microsomal epoxide hydrolase
and glutathione S-transferase M1 and T1. Thorax 2000;
55: 121–5.
32.  Calikoglu M, Tamer L, Ates Aras N, Karakaç S, Ercan B.
The association between polymorphic genotypes of glu-
tathione S-transferases and COPD in the Turkish popula-
tion. Biochem Genet 2006; 44: 307–19.
33.  Imboden M, Downs SH, Senn O, Matyas G, Brändli O,
Russi EW, et al. Glutathione S-transferase genotypes
modify lung function decline in the general population:
SAPALDIA cohort study. Respir Res 2007; 8: 2.
34.  Lakhdar R, Denden S, Mouhamed MH, Chalgoum A,
Leban N, Knani J, et al. Correlation of EPHX1, GSTP1,
GSTM1, and GSTT1 genetic polymorphisms with anti -
oxidative stress markers in chronic obstructive pulmonary
disease. Exp Lung Res 2011; 37: 195–204.
35.  Korytina GF, Akhmadishina LZ, Tselousova OS, Zagi -
dullin ShZ, Viktorova TV. Polymorphism of the genes for
antioxidant defense enzymes and their association with
the development of chronic obstructive pulmonary dis-
ease in the population of Bashkortostan. Genetika 2009;
45: 967–76.
36.  Lakhdar R, Denden S, Knani J, Leban N, Daimi H,
Hassine M, et al. Relationship between glutathione S-
transferase P1 polymorphisms and chronic obstructive
pulmonary disease in a Tunisian population. Genet Mol
Res 2005; 9: 897–907.
37.  Vibhuti A, Arif E, Deepak D, Singh B, Qadar Pasha MA.
Genetic polymorphisms of GSTP1 and mEPHX corre-
late with oxidative stress markers and lung function in
COPD. Biochem Biophys Res Commun 2007; 359:
136–42.
38.  Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A,
Yamakido M. Microsomal epoxide hydrolase genotypes
and chronic obstructive pulmonary disease in Japanese.
Int J Mol Med 2000; 5: 49–53.
39.  Li H, Fu WP, Hong ZH. Microsomal epoxide hydrolase
gene polymorphisms and risk of chronic obstructive pul-
monary disease: A comprehensive meta-analysis. Oncol
Lett 2013; 5: 1022–30.
40.  Lakhdar R, Denden S, Knani J, Leban N, Daimi H, Has -
sine M, et al. Combined analysis of EPHX1, GSTP1,
GSTM1 and GSTT1 gene polymorphisms in relation to
chronic obstructive pulmonary disease risk and lung
function impairment. Dis Markers 2011; 30: 253–63.
41.  He JQ, Ruan J, Connett JE, Anthonisen NR, Paré PD,
Sandford AJ. Antioxidant gene polymorphisms and sus-
ceptibility to a rapid decline in lung function in smokers.
Am J Respir Crit Care Med 2002; 166: 323–8.
214 Stankovi} et al.: Genetic variants of phase I and II genes in COPD 
Received: November 21, 2013
Accepted: December 20, 2013
